In actual clinical practice, such a detection strategy is associated with the popularity of NGS, the value of multigene testing in each cancer type, patient economic condition, the knowledge of molecular pathological testing at each hospital, and, also, NTRK gene fusion prevalence and the possibility of screening with pan‐TRK IHC (TRK protein physiological expression). The gene discussed is NTRK1; the disease is cancer.